
Discontinuation of semaglutide therapy leads to weight gain.
Semaglutide reduces total body weight and adipose tissue mass, reducing energy consumption. This mechanism affects the overall decrease in appetite, including increased satiety signals and attenuation of hunger signals, as well as improved control of food intake and reduced cravings for food. In addition, semaglutide reduces the preference for eating high-fat foods.
Nevertheless, a study by Northwestern University in the USA showed that the majority of patients (up to 85%) stop taking GPP-1 agonists during the first two years due to the high cost of the drug (in the Russian Federation, the cost of GPP-1 drugs is several thousand rubles per package with 1 syringe pen) or due to with the achievement of the target weight. Subsequently, they regain up to 67% of the lost body weight and note a deterioration in their health.
Weight gain has also been noted in other studies. For example, in 2022, most participants in the STEP-1 clinical trial regained up to 2/3 of their previously lost weight a year after giving up the drug.
In Russia, semaglutide preparations are represented by seven trade names. Five drugs are produced in Russia, the other two in Denmark.
It is worth noting that the documentation for consumers (instructions for medical use, leaflet) indicates that semaglutide preparations are indicated for use in patients with type 2 diabetes mellitus on the background of diet and exercise. Weight loss requires a comprehensive approach.
There are no miracles.